AI-generated from publicly available materials.Strolll, a UK-based MedTech company specializing in augmented reality applications for neurorehabilitation, has successfully raised €5 million in funding, including a significant loan from Innovate UK and investment from IW Capital.
The funding consists of a €4.18 million innovation loan from Innovate UK and an additional €813.2k Growth Catalyst Investor Partnerships award, aimed at supporting two separate projects within the company. This financial boost follows a previous €12.2 million Series A funding round, also led by IW Capital. The CEO, Jorgen Ellis, emphasized the company’s commitment to enhancing rehabilitation for individuals with neurological disorders, stating that this capital will expedite their efforts to improve patient engagement and clinical outcomes.
Founded in 2018, Strolll develops digital therapeutics delivered through AR glasses, facilitating neurorehabilitation for patients both in clinical settings and at home. The neurorehabilitation market is expanding, and Strolll aims to leverage augmented reality to make therapies more engaging and accessible. The Innovate UK loan will specifically fund the development of StrolllAssessment, a platform integrating AI with biomechanics to streamline clinical validation processes, potentially reducing timelines significantly.
Additionally, the GCIP award will support the introduction of StrolllAcute, a system designed for acute, bed-bound patients, allowing for early therapeutic interventions without disrupting existing hospital workflows. Innovate UK's investment reflects confidence in Strolll's technological capabilities and its potential for commercial success, positioning the company for accelerated growth in a vital healthcare sector.